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An attempt to ﬁnd pharmacological therapies to treat stroke patients and minimize the extent of cell death has seen the failure
of dozens of clinical trials. As a result, stroke/cerebral ischemia is the leading cause of lasting adult disability. Stroke-induced cell
death occurs due to an excess release of glutamate. As a consequence to this, a compensatory increased release of GABA occurs that
results in the subsequent internalization of synaptic GABAA receptors and spillover onto perisynaptic GABAA receptors, resulting
in increased tonic inhibition. Recent studies show that the brain can engage in a limited process of neural repair after stroke.
Changes in cortical sensory and motor maps and alterations in axonal structure are dependent on patterned neuronal activity. It
has been assumed that changes in neuronal excitability underlie processes of neural repair and remapping of cortical sensory and
motor representations. Indeed, recent evidence suggests that local inhibitory and excitatory currents are altered after stroke and
modulation of these networks to enhance excitability during the repair phase can facilitate functional recovery after stroke. More
speciﬁcally, dampening tonic GABA inhibition can aﬀord an early and robust improvement in functional recovery after stroke.
1. γ-AminobutyricAcid (GABA)
GABA is the major inhibitory neurotransmitter within the
mammalian brain. Twenty to 50% of all synapses within
the CNS use GABA as a neurotransmitter, mediating both
fast and slow inhibitory synaptic transmission [1]. GABA
is an endogenous ligand for the GABAA, GABAB,a n d
GABAC receptors [2], and these receptor subtypes have been
classiﬁed according to diﬀerences in both structure and
pharmacology. GABAARs are ligand-gated chloride channels
[2, 3] formed from 5 subunits arranged around a central ion
pore. At least nineteen mammalian genes encoding for the
various GABAAR subunits exist: α1–6, β1–3, γ1–3, δ, ε, ϕ, π,
and ρ1–3, with slice variants also contributing to variations
in receptor functions [4–9]. The most common subunit
combinations are believed to be composed of 2α,2 β,a n dγ,
with the γ-subunit being able to be substituted for either an
ε-o raδ-subunit [7–9].
Depolarization of inhibitory interneurons produces a
phasic release of GABA and inhibition of postsynaptic
neurons. Extrasynaptic GABAAR’s respond to ambient levels
of GABA present in the extracellular space to regulate
baseline pyramidal neuron excitability and show reduced
desensitization remaining active for long periods of time
[10]. Tonic GABAAR’s in the hippocampus and cortex con-
tain either α5o rδ-subunits [6, 10]. Reduced activity of α5
or δ-subunits enhances pyramidal neuron ﬁring to aﬀerent
inputs [10–12], enhances neuronal network excitability [13],
and facilitates LTP and cognitive performance [14–17].
GABA transporters modulate the level of tonic GABAAR
activity [18] with the uptake of GABA into neurons and
astrocytes for recycling. Low GABA concentrations activate
extrasynaptic GABAAR’s, leading to persistent or tonic
inhibition [19, 20]. Synaptic and extrasynaptic GABAAR’s
exhibit distinct pharmacological and biophysical properties
that diﬀerentially inﬂuence brain physiology and behavior
[19].
Synaptic GABAAR’s are composed of α1–3, β1–3,a n d
γ1–3, subunits, and the site of action for a variety of
clinically important drugs, such as benzodiazepines, neuros-
teroids, and anesthetics. Where as extrasynaptic GABAAR’s
are composed of subunit combinations containing α4–6,2 Advances in Pharmacological Sciences
β1–3,a n dγ2-o rδ-subunits. Of these receptors, the δ-
containing GABAAR’s coassembled as α4βδ—located in the
cortex, hippocampus and thalamus—or α6βδ—located in
the cerebellum—that are emerging as unique and funda-
mental players in GABAergic neurotransmission [19]. In
addition to δ-containing GABAAR’s having a functional role
in the cortex, the α5-containing GABAAR’s coassembled
primarily as α5βγ2 have also been implicated in poststroke
repair [21]. Even though the expression of the α5-subunit is
low in the cortex compared to the δ-subunit, greater func-
tional improvements in motor recovery are seen following
modulation of the α5-subunit [21]. The pharmacology of
theseextrasynapticreceptorsisinconsistentbetweenresearch
groups [22] and has been hampered by the lack of selective
agents to probe function in recombinant, native, and whole
animal systems [23]. Conﬂicting data is also present with
respect for the ability of these receptors to desensitize [19,
24]. Determining the composition and pharmacology of
this receptor will enable the development of much needed
t h e r a p i e sf o ru s ei ns t r o k e .
1.1. Disability in Stroke. Stroke is the leading cause of death
andlong-termdisabilityinadultsworldwide.Stroke-induced
sensory and motor loss of limb function, in particular,
prevents patients from returning to work and accounts for
the statistic that almost one-third of stroke survivors become
institutionalizedafterhavingastroke[25–28].Recentstudies
have shown that the brain has a limited capacity to repair
after stroke. In both humans and animals, neural repair
after stroke has been shown to involve remapping of
cognitive functions and sprouting of new connections in
tissue adjacent to the stroke site, the peri-infarct cortex [29,
30]. However, mechanisms associated with poststroke neural
repair and recovery have not been well characterized, and it
has been assumed that changes in cortical representational
maps underlying the recovery involve changes in neuronal
excitability. Consistent with this, animal studies suggest
that therapies associated with rehabilitation can promote
plasticity changes in tissue that survives the stroke [31].
Functional recovery within the peri-infarct cortex
involves changes in neuronal excitability. Clinical studies
using direct current stimulation of the peri-infarct cortex,
with protocols that boost local neuronal excitability, have
been shown to improve use of the aﬀected limb in stroke
patients [32, 33]. Furthermore, forced use or task-speciﬁc
repetition of the aﬀected limb have also been shown to
activatetheperi-infarctcortexandimprovefunctionalrecov-
ery [34]. Studies suggest that decreases in γ-aminobutyric
acid GABA activity within the motor cortex could facilitate
structural changes [35] and promote recovery of motor
function [36]. Alterations in neuronal excitability underlie
fundamental changes in information transfer in neuronal
circuits [37] such as long-term potentiation and depression
(LTP and LTD) as well as the unmasking of quiescent
synaptic connections and remodeling of cortical maps [38].
Furthermore, changes in LTP and cortical map formation
occur within the peri-infarct cortex adjacent to the stroke
[29].Thesedatasuggestacriticalroleformodulatingcortical
excitability as a means for promoting functional recovery
after stroke.
1.2. Brain Excitability in Learning, Memory, and Repair. The
processes of neurorehabilitation involve physical, occupa-
tional, and cognitive therapies [27, 28]. Further changes in
poststroke cortical plasticity play a critical role in mediating
repair mechanisms. While these modalities clearly promote
functional recovery, no drug treatments exist that pro-
mote poststroke brain repair and recovery. Recent evidence
suggests that suppression of either cortical tonic GABA
inhibition or stimulation of α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor currents can
promote poststroke function gain [21, 39]. This ability
to regain function relies heavily on the ability to learn
or relearn after stroke and likely follows classical activity-
dependent processes associated with motor learning and
memory[40,41].Inadditiontothesebehaviorallinks,stroke
recovery and classical learning and memory pathways share
similar molecular and cellular links. For instance, genes that
are important for learning and memory are also elevated
during periods of poststroke repair and include membrane-
associated phosphoproteins GAP43 and MARCKS, the tran-
scription factor c-jun, and the cell adhesion molecule L1
[42].
Modulation of learning and memory pathways have
previously been shown to promote functional recovery
and poststroke axonal sprouting following administration
of pharmacological agents such as amphetamines and
phosphodiesterase type-4 inhibitors that boost cAMP/CREB
signaling and learning and memory function [43, 44].
These data indicate that manipulating learning and memory
pathways can oﬀer a novel means for promoting recovery. As
with stroke recovery, the processes of learning and memory
can be enhanced by manipulations that increase neuronal
excitability, which has also been shown to promote function
recovery [21]. Signiﬁcant data is accumulating indicating an
imbalance in inhibitory and excitatory pathways after stroke,
and modulation of these pathways by either enhancing
glutamate-mediated transmission or dampening the tonic
form of GABA can facilitate functional recovery [21, 39, 45–
48]. α5GABAAR negative allosteric modulators are part of
a broad class of drugs that boost learning and memory
function by inﬂuencing key elements in neuronal memory
storage, such as LTP [14, 16]. α5GABAARn e g a t i v ea l l o s t e r i c
modulators, and indeed any mechanism that dampens tonic
GABA signaling, could signiﬁcantly improve poststroke
recovery [21]. This suggests that the similarities between
neuronal mechanisms of learning and memory and those of
functionalrecoveryafterstrokeextendtocommontreatment
strategies for both.
Most strategies that promote functional recovery after
stroke, such as axonal sprouting, neurogenesis, or angio-
genesis, focus or rely on inducing structural changes in
the brain as a means to promote functional recovery after
stroke [49–53]. In order to promote structural change in
the brain, however, these treatments take time to develop aAdvances in Pharmacological Sciences 3
functional eﬀect. Blocking tonic GABA inhibition induces
a rapid improvement in behavioral recovery in the absence
of any change in axonal sprouting within the peri-infarct
cortex [21]. This data suggests that treatments that focus on
inducing molecular memory systems after stroke may have
theadvantageofpromoting synaptic plasticity in peri-infarct
cortex rapidly and without altering the tissue reorganization
that normally occurs after stroke. These therapies are highly
translatable into the clinic due to their timing of drug
administration, 3–7 days after stroke in rodents, and with
the early eﬀects seen with functional recovery, will aid in the
huge social and economical burdens seen after stroke.
1.3. Attenuating GABAA Receptor Function in Neural Repair
after Stroke. As with stroke recovery, the processes of
learning and memory can be enhanced by manipulations
thatincreaseneuronalexcitability.However,unlikethestroke
recovery ﬁeld, basic science studies in learning and memory
have deﬁned speciﬁc cellular pathways that lead to enhanced
neuronal excitability and improved function.
Recent work has shown that enhanced neuronal
excitability occurs following the dampening of the baseline
level of inhibition in neurons. This baseline inhibition is in
part set by a tonic, always present, degree of inhibitory sig-
naling from the major inhibitory neurotransmitter, GABA.
Unlike the phasic nature of synaptically released GABA, the
action of GABA via extrasynaptic receptors is to tonically
suppress neuronal excitability and to help regulate neuronal
action potential ﬁring. These extrasynaptic GABA receptors
consist of α5a n dδ-subunit containing GABAAR’s. Recent
evidence using α5GABAAR “knock-out”, and point-mutated
mice have clearly shown that the α5-subunit plays a key role
in cognitive processing [15, 17]. In addition, in vitro and
in vivo work has shown that α5GABAARn e g a t i v ea l l o s t e r i c
modulators can enhance cognition within the Morris water
maze, enhance hippocampal LTP and do not have any
proconvulsant eﬀects [14, 16]. Using pharmacological and
genetic manipulations of extrasynaptic GABAAR’s, we have
shown marked improvements in functional recovery when
starting treatments from 3 days after the stroke [21]. These
data are consistent for oﬀering a potential role for extrasy-
naptic GABAAR’s in processes involving synaptic plasticity
and learning and memory and more recently poststroke
recovery.
Neuronal inhibition and network function is disturbed
in peri-infarct tissue during periods of cortical plasticity,
re-mapping, and recovery. The increase in tonic inhibition
in cortical pyramidal neurons reported by Clarkson and
colleagues [21] occurs at precisely the same time as cortical
map plasticity and recovery [54]. Behavioral recovery in
stroke is closely correlated with functional plasticity in peri-
infarct and connected cortical regions. In human stroke
patients, an expansion in motor representation maps is
seen in tissue adjacent to or connected to stroke [29, 55].
In animal models, when stroke damages primary motor
or somatosensory areas, motor and sensory representations
remap in peri-infarct cortex [54, 56]. These processes of
recovery identify plasticity in the cortical circuits in peri-
infarct cortex as key elements in functional recovery.
2.GAB AandC e r eb ralI sc he mia
A large body of work has been devoted to developing and
exploring neuroprotectants that act to block glutamate-
mediated neurotransmission in animal models of cerebral
ischemia [57, 58]. Increased inhibitory neurotransmission
associated with GABA has been shown to normalize the
balance of glutamate-mediated excitation. Therefore, phar-
macological enhancement of GABAAR neurotransmission
provides an alternative means for neuroprotection. Indeed,
over recent years, changes in GABA function following cere-
bral ischemia and possible protective beneﬁts of GABAergic
drugs have been extensively assessed [59–65]. Even though
it has been proposed that enhancing GABA transmission
may elicit protection against cerebral ischemia [60–62,
65], the exact mechanisms that are associated with these
neuroprotectants have, as yet, not been fully elucidated
and increasing GABA function may be protective during
cerebral ischemia for diﬀerent reasons [59–65]. However,
even though GABA agonists have shown great promise in
animal model, these compounds have failed to translate into
the clinic [66, 67]. The failure of these compounds highlights
the need to ﬁrstly establish better preclinical rodent models
ofstrokethatbettermimicwhatoccursinhumans.Secondly,
the use of subunit speciﬁc GABA compounds is more likely
to show an eﬀect, due to them having less side eﬀects, such
as drug-induced hypothermia and sedation. However, even
with recent developments in this area, studies are lacking.
The need to assess subunit-speciﬁc GABA compounds to
help understand what is happening after stroke in terms of
GABA function is highlighted with clinical reports showing
that zolpidem, an α1 subunit GABAAR modulator, can result
intransientlyimprovesinaphasiainchronicstrokesurvivors
[68].
During situations of cerebral ischemia, it has been shown
that the extracellular concentrations of GABA increase
(approx. 50 fold compared to basal levels) to the micromolar
range [59, 69] and remain elevated for at least 30 minutes
during periods of reperfusion. Prolonged exposure of the
GABAARs to high concentrations of GABA agonists in
vitro has routinely been shown to become desensitized
and/or downregulated [70–72]. Similarly, the GABAARi s
also downregulated in the gerbil hippocampus following
transient cerebral ischemia [63]. In this model, receptor
downregulation was shown to be via internalization, as
there was a rapid decrease in binding of the hydrophilic
ligand[3H]-SR-95531,butnotthehydrophobicligand[3H]-
ﬂunitrazepam [63]. This increase in extracellular GABA is
likely to result in the spill over onto peri-synaptic GABAAR’s
resulting in an increase in tonic inhibition. Indeed, recent
evidence showing an increase in tonic inhibition after stroke
supports this notion [21]. This increase in tonic inhibition
is most likely a safety mechanism imposed by the brain as
a means to minimize neuronal damage. However, as this4 Advances in Pharmacological Sciences
increase in tonic inhibition persists for at least 2 weeks after
the stroke, this safety mechanism which is likely to have
either wrong or no feedback mechanism has been formed to
compensate for such a change in tonic GABA.
3. Poststroke Tonic Inhibition
Changes in neuronal excitability, loss of GABAergic inhi-
bition, enhanced glutamatergic transmission, and synaptic
plasticity all contribute to neuronal reorganization after
stroke. Studies that promote an increase in local brain
excitability result in improved function [21, 34, 39, 45]a n d
suggest that decreasing GABA activity within the brain could
facilitatestructuralchangesthatpromotefunctionalrecovery
[21, 34, 45]. In particular, this enhancement of neuronal
excitability involves dampening baseline levels of inhibition.
Tonic or continuous signaling from GABA sets baseline
inhibition. GABA acts via extrasynaptic GABAAR’s to ton-
ically suppress neuronal excitability and regulate neuronal
action potential ﬁring. Therefore, in order to facilitate func-
tional recovery, an increase in brain excitability is required
to overcome this hypofunctionalism [34]. Recently Clarkson
and colleagues have demonstrated marked improvements
in poststroke functional recovery using pharmacological
manipulations of extrasynaptic GABAAR’s, implicating α5
or δ-containing GABAAR’s as novel targets for developing
agents to help stroke suﬀerers.
GABA has been shown to mediate both fast and slow
inhibitory synaptic transmission [1]. During development,
however, the GABAARs have been shown to mediate
excitation as well as play an important role in neural
migration and synaptogenesis [73, 74]. During situations of
cerebral ischemia, extracellular concentrations of GABA are
signiﬁcantly elevated [59, 69], resulting in GABAA receptor
desensitization and/or downregulation [63, 71]. This is
supported by immunohistochemical and autoradiographic
data showing decreased expression of α1, α2, α3, α5, and
γ2 subunits following photothrombotic stroke and freeze-
lesion-induced cortical injury [75–77].
Recent work has shown that epileptogenesis results in
the suppression of functionally active α5GABAARs and
results in an increase/substitution of other GABAAR’s with
a subsequent increase in rather than suppression of tonic
inhibitory currents [78]. A similar compensatory increase
in α4δ-mediated tonic currents has been seen in the α5
knockout mice within region CA1 of the hippocampus [11].
Extracellular GABA concentrations and thus tonic inhibition
have been shown to increase as the excitatory drive increases
resulting in the modulation of neuronal excitability and
prevention of neuronal saturation [79]. Consistent with
these ﬁndings, Clarkson and colleagues reported an increase
inGABAtonicinhibitorycurrentsfrom3–14dayspoststroke
in layer II cortical pyramidal neurons [21]. This poststroke
increase in tonic inhibition may act as a compensatory
mechanism to prevent further neuronal injury. However,
this prolonged increase in tonic inhibition during the
repair phase is acting as a hindrance by preventing cortical
expansion and improvements in functional recovery. This
is supported by ﬁndings by Clarkson and colleagues who
show that both pharmacological and genetic modulation
of tonic inhibition, dampening either α5o rδ-mediated
increase in tonic GABA currents, results in early and marked
improvements in functional recovery [21].
Understanding the proﬁle for which cortical plasticity
occurs, altered after a stroke, is critical for fully determin-
ing when to start treatments and with what therapeutic
compound to use. Based on our ﬁndings, we have clearly
shown that dampening of tonic GABA currently from 3
days results in robust functional improvements of motor
recovery [21]. These improvements, however, may not be
the same if treatments are started weeks after stroke onset
as previously shown in humans using zolpidem, which was
shown to transiently improve aphasia in chronic stroke
survivors [68]. The α1a n dβ2 GABAAR subunits are densely
localized within the cortex and coassembly with the γ2-
subunit accounts for about 40% of all GABAARs within the
cortex [80]. Assembly of GABAARs containing α1β2γ2h a s
been shown to be enriched at synaptic sites throughout the
cortex [81] and involved in changes in synaptic plasticity.
However, studies have also shown that the δ subunit can
coassemble with α1 subunits to form functional recombi-
nant receptors[82, 83]. Furthermore, immunoprecipitation
studies have shown that δ subunits can associate with α1
subunits [84], and GABAARα1 subunits have also been
found extrasynaptically [85, 86] consistent with the typical
localization of δ-containing GABAARs8181. These data could
suggest an alternative method for why zolpidem was having
an eﬀect in chronic stroke patients to alleviate the burden of
aphasia.However,furtherstudiesareneeded,asoneprevious
study would suggest that the γ2-subunit is required in order
for zolpidem to have an eﬀect [87].
4. DampeningCortical Inhibition Alters
Cortical Responsiveness
Disinhibition of cortical connections within the peri-infarct
or regions associated with the peri-infarct cortex have been
argued as either occurring as a direct consequence of the
stroke or as a potential compensatory mechanism related to
the recovery [88]. This argument has come about based on a
number of observations such as local blockage of GABAergic
inhibition unmasking preexisting horizontal connections
within the rat motor cortex [38]; LTP of adult rat motor
cortex horizontal connections is dependent on GABA disin-
hibition during theta burst stimulation, unlike other regions
such as the hippocampus or somatosensory cortex [35]; and
ﬁnally modulation of GABA has been shown to be involved
in learning in healthy humans as shown using imaging
studies showing a correlation between a decrease in GABA
concentration in motor cortex and motor skill learning
[89]. Consistent with the notion that cortical disinhibition
is occurring as a compensatory mechanism, Clarkson and
colleagues have shown a robust and persistent increase in
tonic inhibition in the peri-infarct cortex after stroke and
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extrasynaptic GABAAR negative allosteric modulator, L655-
708, exacerbated the lesion [21]. Further to this, Clarkson
and colleagues showed for the ﬁrst time that delayed
treatment L655-708, which has previously been shown to
induce LTP [14], provides an early and robust reversal in
behavioral deﬁcits [21]. Given the early behavioral eﬀects
seen and the lack of eﬀect on sprouting of new connections,
cortical disinhibition following L655-708-treatment seems
a logical argument. To support the notion that dampening
GABA activity is having a beneﬁcial eﬀect, no improvement
in motor function was observed after stroke following
administration of the GABA agonist, muscimol [21]. This
is backed by clinical studies illustrating the reemergence
of stroke symptoms following administration of the GABA
agonist midazolam in chronic stroke patients that have
shown signiﬁcant improvements in function [90]. The peri-
infarctcortexexhibitsneuronalmetabolicdysfunctionovera
one-month period [91], which would indicate a therapeutic
time window forblockade of tonic GABA signaling of at least
one month after stroke. Consistent with this is the fact, when
L655-708 treatment is discontinued after a two-week period
ofadministrationafterstroke,aslightreboundeﬀect/reversal
in functional recovery is observed compared to animals that
received treatment for the six-week period [21].
5. Conclusions
Therapies that promote functional recovery after stroke are
limited to physical rehabilitation measures. While speciﬁc
measures, such as constraint-induced therapies, promote
recovery of motor function, no pharmacological therapies
are available that aid in recovery. Functional recovery after
stroke follows psychological learning rules [41] that indicate
learning and memory principles may underlie behavioral
recovery. At the cellular level, learning and memory are
mediated by speciﬁc excitatory neuronal responses, such as
LTP, and are potentiated by drugs that facilitate aspects of
excitatory neuronal signaling [13], such as tonic GABAAR
antagonists [10]. Recent data shows that stroke alters the
balance of excitatory and inhibitory inputs to neurons in the
peri-infarctcortex,byincreasinginhibitorytone.Thisaltered
excitatory balance occurs through a decrease in the normal
cellular uptake of GABA. Dampening GABA-mediated tonic
inhibition restores the excitatory/inhibitory balance in peri-
infarct motor cortex ex vivo and promotes recovery of motor
function in vivo. These eﬀects occur through blockade of
α5o rδ-containing GABAAR’s. This data indicates a novel
role for tonic GABAAR function in promoting poststroke
recovery most likely via cortical disinhibition [38, 92, 93]
and suggests a new avenue for pharmacological treatment
of neurorehabilitation in stroke. This early eﬀect on stroke
recovery opens the possibility for treatments that block tonic
GABA signaling and may be used in conjunction with later-
acting stroke repair therapies in a combinatorial manner.
More generally, tonic GABA signaling has a biphasic role
in stroke. Early tonic GABA signaling limits stroke size,
later tonic GABA signaling limits stroke recovery. These
data identify a promising molecular system for future stroke
recovery therapies and implicate molecular memory systems
as likely key players in recovery from stroke.
Acknowledgments
This paper was completed during tenure of a Repatriation
Fellowship from the New Zealand Neurological Foundation
and the Sir Charles Hercus Fellowship from the Health
Research Council of New Zealand.
References
[1] W. Sieghart, “Structure and pharmacology of γ-aminobutyric
acid(A) receptor subtypes,” Pharmacological Reviews, vol. 47,
no. 2, pp. 181–234, 1995.
[2] M.ChebibandG.A.R.Johnston,“The“ABC”ofGABArecep-
tors: a brief review,” Clinical and Experimental Pharmacology
and Physiology, vol. 26, no. 11, pp. 937–940, 1999.
[ 3 ]C .D ’ H u l s t ,J .R .A t a c k ,a n dR .F .K o o y ,“ T h ec o m p l e x i t yo f
the GABAA receptor shapes unique pharmacological proﬁles,”
Drug Discovery Today, vol. 14, no. 17-18, pp. 866–875, 2009.
[ 4 ]R .L .M a c d o n a l da n dR .W .O l s e n ,“ G A B A Ar e c e p t o rc h a n -
nels,” Annual Review of Neuroscience, vol. 17, pp. 569–602,
1994.
[5] R. W. Olsen and W. Sieghart, “International Union of Phar-
macology. LXX. Subtypes of γ-aminobutyric acidA receptors:
classiﬁcation on the basis of subunit composition, pharmacol-
ogy, and function. Update,” Pharmacological Reviews, vol. 60,
no. 3, pp. 243–260, 2008.
[ 6 ]R .W .O l s e na n dW .S i e g h a r t ,“ G A B A A receptors: subtypes
provide diversity of function and pharmacology,” Neurophar-
macology, vol. 56, no. 1, pp. 141–148, 2009.
[7] N. P. Barrera, J. Betts, H. You et al., “Atomic force microscopy
reveals the stoichiometry and subunit arrangement of the
α4β3δ GABAA receptor,” Molecular Pharmacology, vol. 73, no.
3, pp. 960–967, 2008.
[8] P. J. Whiting, “The GABAA receptor gene family: new oppor-
tunities for drug development,” Current Opinion in Drug
Discovery and Development, vol. 6, no. 5, pp. 648–657, 2003.
[9] P. J. Whiting, “GABA-A receptor subtypes in the brain: a
paradigmforCNSdrugdiscovery?”DrugDiscoveryToday,vol.
8, no. 10, pp. 445–450, 2003.
[10] J. Glykys and I. Mody, “Activation of GABAA receptors: views
from outside the synaptic cleft,” Neuron,v o l .5 6 ,n o .5 ,p p .
763–770, 2007.
[11] J. Glykys and I. Mody, “Hippocampal network hyperactivity
afterselectivereductionoftonicinhibitioninGABAA receptor
α5subunit-deﬁcientmice,”JournalofNeurophysiology,vol.95,
no. 5, pp. 2796–2807, 2006.
[12] K. R. Drasbek and K. Jensen, “THIP, a hypnotic and antinoci-
ceptive drug, enhances an extrasynaptic GABAA receptor-
mediated conductance in mouse neocortex,” Cerebral Cortex,
vol. 16, no. 8, pp. 1134–1141, 2006.
[13] M. C. Walker and A. Semyanov, “Regulation of excitability by
extrasynaptic GABAA receptors,” Results and Problems in Cell
Diﬀerentiation, vol. 44, pp. 29–48, 2008.
[ 1 4 ]J .R .A t a c k ,P .J .B a y l e y ,G .R .S e a b r o o k ,K .A .W a ﬀord, R. M.
McKernan, and G. R. Dawson, “L-655,708 enhances cognition6 Advances in Pharmacological Sciences
in rats but is not proconvulsant at a dose selective for α5-
containing GABAA receptors,” Neuropharmacology, vol. 51,
no. 6, pp. 1023–1029, 2006.
[15] N. Collinson, F. M. Kuenzi, W. Jarolimek et al., “Enhanced
learning and memory and altered GABAergic synaptic trans-
mission in mice lacking the α5 subunit of the GABAA
receptor,” Journal of Neuroscience, vol. 22, no. 13, pp. 5572–
5580, 2002.
[16] G. R. Dawson, K. A. Maubach, N. Collinson et al., “An
inverse agonist selective for α5 subunit-containing GABA A
receptors enhances cognition,” Journal of Pharmacology and
Experimental Therapeutics, vol. 316, no. 3, pp. 1335–1345,
2006.
[17] F. Crestani, R. Keist, J. M. Fritschy et al., “Trace fear
conditioning involves hippocampal α5 GABAA receptors,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 13, pp. 8980–8985, 2002.
[18] S. Keros and J. J. Hablitz, “Subtype-speciﬁc GABA transporter
antagonists synergistically modulate phasic and tonic GABAA
conductances in rat neocortex,” Journal of Neurophysiology,
vol. 94, no. 3, pp. 2073–2085, 2005.
[19] D. Belelli, N. L. Harrison, J. Maguire, R. L. Macdonald, M.
C. Walker, and D. W. Cope, “Extrasynaptic GABAa receptors:
form, pharmacology, and function,” Journal of Neuroscience,
vol. 29, no. 41, pp. 12757–12763, 2009.
[20] I. Mody, “Distinguishing between GABAA receptors respon-
sible for tonic and phasic conductances,” Neurochemical
Research, vol. 26, no. 8-9, pp. 907–913, 2001.
[ 2 1 ]A .N .C l a r k s o n ,B .S .H u a n g ,S .E .M a c I s a a c ,I .M o d y ,a n d
S. T. Carmichael, “Reducing excessive GABA-mediated tonic
inhibition promotes functional recovery after stroke,” Nature,
vol. 468, no. 7321, pp. 305–309, 2010.
[22] C. M. Borghese and R. A. Harris, “Studies of ethanol actions
on recombinant δ-containing γ-aminobutyric acid type A
receptors yield contradictory results,” Alcohol, vol. 41, no. 3,
pp. 155–162, 2007.
[23] K. A. Waﬀord, M. B. van Niel, Q. P. Ma et al., “Novel
compounds selectively enhance δ subunit containing GABAA
receptorsandincreasetoniccurrentsinthalamus,”Neurophar-
macology, vol. 56, no. 1, pp. 182–189, 2009.
[24] D. P. Bright, M. Renzi, J. Bartram et al., “Profound desensi-
tization by ambient GABA limits activation of δ-containing
GABAA receptors during spillover,” Journal of Neuroscience,
vol. 31, no. 2, pp. 753–763, 2011.
[25] Y. S. Ng, J. Stein, M. Ning, and R. M. Black-Schaﬀer, “Com-
parison of clinical characteristics and functional outcomes of
ischemicstrokeindiﬀerentvascularterritories,”Stroke,vol.38,
no. 8, pp. 2309–2314, 2007.
[26] S.M.Lai,S.Studenski,P.W.Duncan,andS.Perera,“Persisting
consequences of stroke measured by the stroke impact scale,”
Stroke, vol. 33, no. 7, pp. 1840–1844, 2002.
[27] B. H. Dobkin, “Training and exercise to drive poststroke
recovery,” Nature Clinical Practice Neurology,v o l .4 ,n o .2 ,p p .
76–85, 2008.
[28] B. H. Dobkin, “Strategies for stroke rehabilitation,” Lancet
Neurology, vol. 3, no. 9, pp. 528–536, 2004.
[29] S. T. Carmichael, “Cellular and molecular mechanisms of
neural repair after stroke: making waves,” Annals of Neurology,
vol. 59, no. 5, pp. 735–742, 2006.
[30] R. J. Nudo, “Mechanisms for recovery of motor function
following cortical damage,” Current Opinion in Neurobiology,
vol. 16, no. 6, pp. 638–644, 2006.
[31] M. A. Maldonado, R. P. Allred, E. L. Felthauser, and T.
A. Jones, “Motor skill training, but not voluntary exercise,
improves skilled reaching after unilateral ischemic lesions
of the sensorimotor cortex in rats,” Neurorehabilitation and
Neural Repair, vol. 22, no. 3, pp. 250–261, 2008.
[32] M. Alonso-Alonso, F. Fregni, and A. Pascual-Leone, “Brain
stimulation in poststroke rehabilitation,” Cerebrovascular Dis-
eases, vol. 24, no. 1, supplement 1, pp. 157–166, 2007.
[33] F. C. Hummel and L. G. Cohen, “Non-invasive brain stim-
ulation: a new strategy to improve neurorehabilitation after
stroke?” Lancet Neurology, vol. 5, no. 8, pp. 708–712, 2006.
[34] G. F. Wittenberg and J. D. Schaechter, “The neural basis of
constraint-induced movement therapy,” Current Opinion in
Neurology, vol. 22, no. 6, pp. 582–588, 2009.
[35] G. Hess, C. D. Aizenman, and J. P. Donoghue, “Conditions
for the induction of long-term potentiation in layer II/III
horizontal connections of the rat motor cortex,” Journal of
Neurophysiology, vol. 75, no. 5, pp. 1765–1778, 1996.
[36] P. Cicinelli, P. Pasqualetti, M. Zaccagnini, R. Traversa, M.
Oliveﬁ, and P. M. Rossini, “Interhemispheric asymmetries
of motor cortex excitability in the postacute stroke stage: a
paired-pulse transcranial magnetic stimulation study,” Stroke,
vol. 34, no. 11, pp. 2653–2658, 2003.
[37] A. Citri and R. C. Malenka, “Synaptic plasticity: multiple
forms, functions, and mechanisms,” Neuropsychopharmacol-
ogy, vol. 33, no. 1, pp. 18–41, 2008.
[38] K. M. Jacobs and J. P. Donoghue, “Reshaping the cortical
motor map by unmasking latent intracortical connections,”
Science, vol. 251, no. 4996, pp. 944–947, 1991.
[ 3 9 ]A .N .C l a r k s o n ,J .J .O v e r m a n ,S .Z h o n g ,R .M u e l l e r ,G .
Lynch, and S. T. Carmichael, “AMPA receptor-induced local
brain-derived neurotrophic factor signaling mediates motor
recovery after stroke,” Journal of Neuroscience, vol. 31, no. 10,
pp. 3766–3775, 2011.
[40] J. M. Conner, A. A. Chiba, and M. H. Tuszynski, “The basal
forebrain cholinergic system is essential for cortical plasticity
and functional recovery following brain injury,” Neuron, vol.
46, no. 2, pp. 173–179, 2005.
[41] J. W. Krakauer, “Motor learning: its relevance to stroke recov-
ery and neurorehabilitation,” Current Opinion in Neurology,
vol. 19, no. 1, pp. 84–90, 2006.
[42] S. T. Carmichael, I. Archibeque, L. Luke, T. Nolan, J. Momiy,
andS.Li,“Growth-associatedgeneexpressionafterstroke:evi-
dence for a growth-promoting region in peri-infarct cortex,”
Experimental Neurology, vol. 193, no. 2, pp. 291–311, 2005.
[43] R. P. Stroemer, T. A. Kent, and C. E. Hulsebosch, “Enhanced
neocortical neural sprouting, synaptogenesis, and behav-
ioral recovery with D-amphetamine therapy after neocortical
infarction in rats,” Stroke, vol. 29, no. 11, pp. 2381–2395, 1998.
[44] E. MacDonald, H. van der Lee, D. Pocock et al., “A
novel phosphodiesterase type 4 inhibitor, HT-0712, enhances
rehabilitation-dependent motor recovery and cortical reorga-
nization after focal cortical ischemia,” Neurorehabilitation and
Neural Repair, vol. 21, no. 6, pp. 486–496, 2007.
[45] A. N. Clarkson and S. T. Carmichael, “Cortical excitability and
post-strokerecovery,”BiochemicalSocietyTransactions,vol.37,
no. 6, pp. 1412–1414, 2009.
[46] S.Schmidt,C.Bruehl,C.Frahm,C.Redecker,andO.W.Witte,
“Age dependence of excitatory-inhibitorybalance following
stroke,” Neurobiology of Aging. In press.
[47] S. Schmidt, C. Redecker, C. Bruehl, and O. W. Witte,
“Age-related decline of functional inhibition in rat cortex,”
Neurobiology of Aging, vol. 31, no. 3, pp. 504–511, 2010.
[48] N. Jaenisch, O. W. Witte, and C. Frahm, “Downregulation of
potassium chloride cotransporter KCC2 after transient focal
cerebral ischemia,” Stroke, vol. 41, no. 3, pp. e151–e159, 2010.Advances in Pharmacological Sciences 7
[49] S. T. Carmichael, “Targets for neural repair therapies after
stroke,” Stroke, vol. 41, no. 10, supplement, pp. S124–S126,
2010.
[50] S. T. Carmichael, “Themes and strategies for studying the
biologyofstrokerecoveryinthepoststrokeepoch,”Stroke,vol.
39, no. 4, pp. 1380–1388, 2008.
[ 5 1 ]J .J .O h a b ,S .F l e m i n g ,A .B l e s c h ,a n dS .T .C a r m i c h a e l ,“ A
neurovascular niche for neurogenesis after stroke,” Journal of
Neuroscience, vol. 26, no. 50, pp. 13007–13016, 2006.
[52] Z. G. Zhang and M. Chopp, “Neurorestorative therapies for
stroke: underlying mechanisms and translation to the clinic,”
The Lancet Neurology, vol. 8, no. 5, pp. 491–500, 2009.
[53] J. Liauw, S. Hoang, M. Choi et al., “Thrombospondins 1 and
2 are necessary for synaptic plasticity and functional recovery
after stroke,” Journal of Cerebral Blood Flow and Metabolism,
vol. 28, no. 10, pp. 1722–1732, 2008.
[54] C. E. Brown, K. Aminoltejari, H. Erb, I. R. Winship, and T. H.
Murphy, “In vivo voltage-sensitive dye imaging in adult mice
reveals that somatosensory maps lost to stroke are replaced
over weeks by new structural and functional circuits with
prolonged modes of activation within both the peri-infarct
zone and distant sites,” Journal of Neuroscience, vol. 29, no. 6,
pp. 1719–1734, 2009.
[55] C. Calautti and J. C. Baron, “Functional neuroimaging studies
of motor recovery after stroke in adults: a review,” Stroke, vol.
34, no. 6, pp. 1553–1566, 2003.
[56] R. M. Dijkhuizen, A. B. Singhal, J. B. Mandeville et al.,
“Correlation between brain reorganization, ischemic damage,
and neurologic status after transient focal cerebral ischemia in
rats: a functional magnetic resonance imaging study,” Journal
of Neuroscience, vol. 23, no. 2, pp. 510–517, 2003.
[57] P. Lipton, “Ischemic cell death in brain neurons,” Physiological
Reviews, vol. 79, no. 4, pp. 1431–1568, 1999.
[58] P. Nicotera and S. A. Lipton, “Excitotoxins in neuronal
apoptosis and necrosis,” Journal of Cerebral Blood Flow and
Metabolism, vol. 19, no. 6, pp. 583–591, 1999.
[59] R. D. Schwartz, X. Yu, M. R. Katzman, D. M. Hayden-Hixson,
and J. M. Perry, “Diazepam, given postischemia, protects
selectively vulnerable neurons in the rat hippocampus and
striatum,” Journal of Neuroscience, vol. 15, no. 1, pp. 529–539,
1995.
[60] A. R. Green, A. H. Hainsworth, and D. M. Jackson, “GABA
potentiation: a logical pharmacological approach for the
treatment of acute ischaemic stroke,” Neuropharmacology, vol.
39, no. 9, pp. 1483–1494, 2000.
[61] R. D. Schwartz-Bloom and R. Sah, “γ-aminobutyric acid A
neurotransmission and cerebral ischemia,” J o u r n a lo fN e u r o -
chemistry, vol. 77, no. 2, pp. 353–371, 2001.
[62] R. D. Schwartz-Bloom, K. A. Miller, D. A. Evenson, B. J. Crain,
and J. V. Nadler, “Benzodiazepines protect hippocampal
neurons from degeneration after transient cerebral ischemia:
an ultrastructural study,” Neuroscience, vol. 98, no. 3, pp. 471–
484, 2000.
[63] B. Alicke and R. D. Schwartz-Bloom, “Rapid down-regulation
of GABA(A) receptors in the gerbil hippocampus following
transient cerebral ischemia,” Journal of Neurochemistry, vol.
65, no. 6, pp. 2808–2811, 1995.
[ 6 4 ] A .N .C l a r k s o n ,J .C l a r k s o n ,D .M .J a c k s o n ,a n dI .A .S a m m u t ,
“Mitochondrial involvement in transhemispheric diaschisis
following hypoxia-ischemia: clomethiazole-mediated amelio-
ration,” Neuroscience, vol. 144, no. 2, pp. 547–561, 2007.
[65] A.N.Clarkson,H.Liu,R.Rahman,D.M.Jackson,I.Appleton,
and D. S. Kerr, “Clomethiazole: mechanisms underlying
lasting neuroprotection following hypoxia-ischemia,” FASEB
Journal, vol. 19, no. 8, pp. 1036–1038, 2005.
[66] M. D. Ginsberg, “Neuroprotection for ischemic stroke: past,
present and future,” Neuropharmacology,v o l .5 5 ,n o .3 ,p p .
363–389, 2008.
[67] P. Lyden, A. Shuaib, K. Ng et al., “Clomethiazole acute stroke
study in ischemic stroke (CLASS-I): ﬁnal results,” Stroke, vol.
33, no. 1, pp. 122–128, 2002.
[68] L.Cohen,B.Chaaban,andM.O.Habert,“TransientImprove-
ment of aphasia with zolpidem,” New England Journal of
Medicine, vol. 350, no. 9, pp. 949–950, 2004.
[69] J. R. Ingleﬁeld, J. M. Perry, and R. D. Schwartz, “Postischemic
inhibition of GABA reuptake by tiagabine slows neuronal
death in the gerbil hippocampus,” Hippocampus, vol. 5, no. 5,
pp. 460–468, 1995.
[70] D. J. Cash and K. Subbarao, “Two desensitization processes
of GABA receptor from rat brain. Rapid measurements of
chloride ion ﬂux using quench-ﬂow techniques,” FEBS Letters,
vol. 217, no. 1, pp. 129–133, 1987.
[71] J. R. Huguenard and B. E. Alger, “Whole-cell voltage-clamp
study of the fading of GABA-activated currents in acutely
dissociatedhippocampalneurons,”JournalofNeurophysiology,
vol. 56, no. 1, pp. 1–18, 1986.
[72] M. H. J. Tehrani and E. M. Barnes Jr., “Agonist-dependent
internalization of γ-aminobutyric acid(A)/benzodiazepine
receptorsinchickcorticalneurons,”JournalofNeurochemistry,
vol. 57, no. 4, pp. 1307–1312, 1991.
[73] Y. Ben-Ari, R. Khazipov, X. Leinekugel, O. Caillard, and J. L.
Gaiarsa, “GABA(A), NMDA and AMPA receptors: a develop-
mentally regulated “menage a trois”,” Trends in Neurosciences,
vol. 20, no. 11, pp. 523–529, 1997.
[74] M. M. McCarthy, A. P. Auger, and T. S. Perrot-Sinal, “Getting
excited about GABA and sex diﬀerences in the brain,” Trends
in Neurosciences, vol. 25, no. 6, pp. 307–312, 2002.
[75] C. Redecker, H. J. Luhmann, G. Hagemann, J. M. Fritschy,
a n dO .W .W i t t e ,“ D i ﬀerential downregulation of GABA(A)
receptor subunits in widespread brain regions in the freeze-
lesion model of focal cortical malformations,” Journal of
Neuroscience, vol. 20, no. 13, pp. 5045–5053, 2000.
[76] C. Redecker, W. Wang, J. M. Fritschy, and O. W. Witte,
“Widespread and long-lasting alterations in GABAA-receptor
subtypes after focal cortical infarcts in rats: mediation by
NMDA-dependent processes,” Journal of Cerebral Blood Flow
and Metabolism, vol. 22, no. 12, pp. 1463–1475, 2002.
[77] M. Que, K. Schiene, O. W. Witte, and K. Zilles, “Widespread
up-regulation of N-methyl-D-aspartate receptors after focal
photothrombotic lesion in rat brain,” Neuroscience Letters, vol.
273, no. 2, pp. 77–80, 1999.
[78] A. Scimemi, A. Semyanov, G. Sperk, D. M. Kullmann, and
M. C. Walker, “Multiple and plastic receptors mediate tonic
GABAA receptor currents in the hippocampus,” Journal of
Neuroscience, vol. 25, no. 43, pp. 10016–10024, 2005.
[79] S. J. Mitchell and R. A. Silver, “Shunting inhibition modulates
neuronal gain during synaptic excitation,” Neuron, vol. 38, no.
3, pp. 433–445, 2003.
[80] R. M. McKernan and P. J. Whiting, “Which GABAA-receptor
subtypes really occur in the brain?” Trends in Neurosciences,
vol. 19, no. 4, pp. 139–143, 1996.
[81] M. Farrant and Z. Nusser, “Variations on an inhibitory theme:
phasic and tonic activation of GABAA receptors,” Nature
Reviews Neuroscience, vol. 6, no. 3, pp. 215–229, 2005.8 Advances in Pharmacological Sciences
[82] N. C. Saxena and R. L. Macdonald, “Assembly of GABA(A)
receptor subunits: role of the δ subunit,” Journal of Neuro-
science, vol. 14, no. 11, pp. 7077–7086, 1994.
[83] M. T. Bianchi and R. L. Macdonald, “Neurosteroids shift
partial agonist activation of GABAA receptor channels from
low- to high-eﬃcacy gating patterns,” Journal of Neuroscience,
vol. 23, no. 34, pp. 10934–10943, 2003.
[84] S. Mertens, D. Benke, and H. Mohler, “GABAA receptor
populations with novel subunit combinations and drug
binding proﬁles identiﬁed in brain by α5- and δ-subunit-
speciﬁc immunopuriﬁcation,” Journal of Biological Chemistry,
vol. 268, no. 8, pp. 5965–5973, 1993.
[85] A. Baude, C. Bleasdale, Y. Dalezios, P. Somogyi, and T. Klaus-
berger, “Immunoreactivity for the GABAA receptor α1 sub-
unit, somatostatin and connexin36 distinguishes axoaxonic,
basket, and bistratiﬁed interneurons of the rat hippocampus,”
Cerebral Cortex, vol. 17, no. 9, pp. 2094–2107, 2007.
[86] C. Sun, W. Sieghart, and J. Kapur, “Distribution of α1, α4, γ2,
and δ subunits of GABAA receptors in hippocampal granule
cells,” Brain Research, vol. 1029, no. 2, pp. 207–216, 2004.
[ 8 7 ]D .W .C o p e ,P .W u l ﬀ, A. Oberto et al., “Abolition of zolpidem
sensitivity in mice with a point mutation in the GABAA
receptor γ2 subunit,” Neuropharmacology,v o l .4 7 ,n o .1 ,p p .
17–34, 2004.
[88] J. Liepert, “Motor cortex excitability in stroke before and
after constraint-induced movement therapy,” Cognitive and
Behavioral Neurology, vol. 19, no. 1, pp. 41–47, 2006.
[89] A. Floyer-Lea, M. Wylezinska, T. Kincses, and P. M. Matthews,
“Rapid modulation of GABA concentration in human senso-
rimotor cortex during motor learning,” Journal of Neurophysi-
ology, vol. 95, no. 3, pp. 1639–1644, 2006.
[90] R. M. Lazar, B. F. Fitzsimmons, R. S. Marshall et al.,
“Reemergence of stroke deﬁcits with midazolam challenge,”
Stroke, vol. 33, no. 1, pp. 283–285, 2002.
[91] J. P. van der Zijden, P. van Eijsden, R. A. De Graaf, and
R. M. Dijkhuizen, “1H/13C MR spectroscopic imaging of
regionally speciﬁc metabolic alterations after experimental
stroke,” Brain, vol. 131, no. 8, pp. 2209–2219, 2008.
[ 9 2 ] C .M .S t i n e a r ,J .P .C o x o n ,a n dW .D .B y b l o w ,“ P r i m a r ym o t o r
cortex and movement prevention: where Stop meets Go,”
Neuroscience and Biobehavioral Reviews,v o l .3 3 ,n o .5 ,p p .
662–673, 2009.
[93] J. W. Stinear and W. D. Byblow, “Disinhibition in the
human motor cortex is enhanced by synchronous upper limb
movements,” Journal of Physiology, vol. 543, no. 1, pp. 307–
316, 2002.